A major barrier to AI adoption in pathology labs is finally cracking: complexity. Leica Biosystems, a Danaher company, has added two advanced AI-powered cancer detection products from Tempus to its Aperio AI Store, a unified digital pathology platform designed to let researchers access multiple AI tools through a single, familiar interface rather than juggling separate software for each algorithm.

Why Are Labs Struggling to Adopt AI Pathology Tools?

For years, pathologists have faced a frustrating reality: powerful AI tools exist, but integrating them into daily work is a nightmare. Each vendor's algorithm requires its own software interface, its own learning curve, and its own workflow integration. This fragmentation has slowed adoption of computational pathology, even as the technology becomes more capable. The Aperio AI Store, which launched in October 2025, aims to solve this by bringing curated AI applications directly into the Aperio HALO AP image management system that pathologists already use.

The newly available Tempus products represent a significant expansion of what's available through this unified platform. Paige PanCancer Detect can identify suspicious areas across more than 40 cancer types, powered by Tempus' pathology foundation model, a type of AI trained on vast amounts of pathology data to recognize patterns across diverse cancer presentations. The second product, Paige Prostate, is actually a suite of three specialized AI applications designed specifically for prostate cancer assessment in whole slide images.

What Specific Tools Are Now Available to Researchers?

The Paige product suite includes three distinct applications for prostate cancer analysis:

• Paige Prostate Detect: Identifies suspicious features in prostate tissue samples across H&E-stained whole slide images, the standard tissue staining method used in pathology labs.
• Paige Prostate Grade & Quantify: Provides detailed assessment and measurement of prostate cancer characteristics, helping pathologists grade severity and extent of disease.
• Paige Perineural Invasion: Detects cancer cells invading nerve tissue, a critical prognostic indicator that affects treatment decisions and patient outcomes.

Both the PanCancer Detect and Prostate suite are currently available for research use only and are not intended for diagnostic or clinical use, meaning they support research workflows but cannot yet be used to make patient care decisions.

"Nearly one year after launch, the Aperio AI Store is helping move AI in digital pathology from individual applications toward a more connected and scalable experience. Tempus brings highly differentiated AI capabilities to our ecosystem, giving laboratories more choice while allowing them to access these technologies within a workflow they already know," said Naveen Chandra, vice president and general manager of digital pathology at Leica Biosystems.

Naveen Chandra, Vice President and General Manager of Digital Pathology at Leica Biosystems

How to Streamline AI Adoption in Your Pathology Lab

For laboratories considering AI tools, the unified platform approach offers practical advantages:

• Reduced Complexity: Access multiple AI algorithms through one consistent user interface instead of learning separate software systems for each vendor or application type.
• Faster Integration: New AI tools integrate directly into existing Aperio HALO AP workflows, eliminating the need to redesign laboratory processes or retrain staff on completely new software platforms.
• Scalable Evaluation: Laboratories can test and compare multiple AI applications across diverse cancer types without managing separate software licenses or technical infrastructure for each tool.
• Workflow Continuity: Pathologists work within familiar software they already know, reducing adoption friction and allowing them to focus on interpreting results rather than navigating new interfaces.

This approach addresses what has been a persistent bottleneck in computational pathology adoption. Even when AI tools are technically superior, labs hesitate to implement them if doing so requires significant workflow disruption or extensive staff retraining.

"Our collaboration with Leica Biosystems allows us to bring our AI-enabled computational pathology products directly into the daily workflows of more researchers worldwide. By embedding the Paige offerings into the Aperio HALO AP software ecosystem, we are making advanced image analysis more accessible, seamless, and actionable for oncology research," stated Razik Yousfi, senior vice president and general manager of AI products at Tempus.

Razik Yousfi, Senior Vice President and General Manager of AI Products at Tempus

The partnership reflects a broader shift in how AI tools are being deployed in specialized fields. Rather than expecting users to adopt entirely new software ecosystems, vendors are increasingly embedding AI capabilities into platforms where professionals already work. This pragmatic approach has proven more effective at driving real-world adoption than releasing powerful tools that require significant operational changes.

The Aperio AI Store will be showcased at the Digital Pathology Association's Pathology Visions 2026 conference, taking place October 16-18 in San Diego, California. Leica Biosystems will demonstrate live applications and discuss how flexible, end-to-end solutions help laboratories of all sizes generate high-quality pathology insights that support research breakthroughs and improved patient outcomes.